Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory/Relapsed Indolent Non-Hodgkin Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06458439
What this trial is testing

Epcoritamab-CAR T Cells for Large B-cell Lymphomas

Who this might be right for
Lymphoma, Non-HodgkinRelapsed Diffuse Large B Cell LymphomaRefractory Diffuse Large B-cell Lymphoma+2 more
Abramson Cancer Center at Penn Medicine 31
Testing effectiveness (Phase 2)Study completedNCT01994382
What this trial is testing

Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL

Who this might be right for
Follicular Lymphoma (FL/Indolent NHL)Aggressive NHL (a NHL)Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)+2 more
Alexion Pharmaceuticals, Inc. 260
Testing effectiveness (Phase 2)Study completedNCT03711578
What this trial is testing

Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)

Who this might be right for
Non Hodgkin Lymphoma
Rhizen Pharmaceuticals SA 20
Early research (Phase 1)Ended earlyNCT05336409
What this trial is testing

CNTY-101 in Participants With CD19-Positive B-Cell Malignancies

Who this might be right for
R/R CD19-Positive B-Cell MalignanciesIndolent Non-Hodgkin LymphomaAggressive Non-Hodgkin Lymphoma
Century Therapeutics, Inc. 28
Testing effectiveness (Phase 2)Study completedNCT01682044
What this trial is testing

Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma

Who this might be right for
Contiguous Stage II Grade 1 Follicular LymphomaContiguous Stage II Grade 2 Follicular LymphomaContiguous Stage II Grade 3 Follicular Lymphoma+30 more
Roswell Park Cancer Institute 20
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07477366
What this trial is testing

Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma

Who this might be right for
Relapsed B-Cell Non-Hodgkin Lymphoma
ImmunityBio, Inc. 20
Testing effectiveness (Phase 2)Ended earlyNCT00954005
What this trial is testing

Study With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent Lymphoma

Who this might be right for
Indolent Lymphoma
German Low Grade Lymphoma Study Group 56
Testing effectiveness (Phase 2)Study completedNCT03144674
What this trial is testing

INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)

Who this might be right for
Lymphoma
Incyte Corporation 110
Testing effectiveness (Phase 2)Ended earlyNCT00005950
What this trial is testing

506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma

Who this might be right for
Angioimmunoblastic T-cell LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell Lymphoma+7 more
National Cancer Institute (NCI) 111
Testing effectiveness (Phase 2)Study completedNCT00244985
What this trial is testing

Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Roswell Park Cancer Institute 42
Testing effectiveness (Phase 2)Active Not RecruitingNCT05583149
What this trial is testing

Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

Who this might be right for
Refractory Aggressive B-cell LymphomasRefractory B-Cell Non-Hodgkin LymphomaAggressive B-cell NHL+10 more
Patrick C. Johnson, MD 28
Early research (Phase 1)Study completedNCT04136756
What this trial is testing

NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma

Who this might be right for
Multiple MyelomaNon-Hodgkin LymphomaIndolent Non-Hodgkin Lymphoma
Nektar Therapeutics 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT04245839
What this trial is testing

Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

Who this might be right for
Lymphoma, Non-Hodgkin
Celgene 276
Large-scale testing (Phase 3)Ended earlyNCT00060671
What this trial is testing

Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma, FollicularLymphoma, Mixed-Cell, FollicularLymphoma, Small Cleaved-Cell, Follicular+1 more
CTI BioPharma 800
Large-scale testing (Phase 3)WithdrawnNCT00577161
What this trial is testing

Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL

Who this might be right for
Non-Hodgkin's Lymphoma
CTI BioPharma
Early research (Phase 1)UnknownNCT03588598
What this trial is testing

Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignancies

Who this might be right for
Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)B-Cell Non-Hodgkin Lymphomas(NHL)
Nanjing Sanhome Pharmaceutical, Co., Ltd. 40
Early research (Phase 1)Study completedNCT00621452
What this trial is testing

Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma

Who this might be right for
B-cell Chronic Lymphocytic LeukemiaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell Lymphoma+8 more
Fred Hutchinson Cancer Center 12
Early research (Phase 1)Looking for participantsNCT06015880
What this trial is testing

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell LymphomaTransformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI) 30
Early research (Phase 1)Looking for participantsNCT05418088
What this trial is testing

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Who this might be right for
Recurrent Acute Lymphoblastic LeukemiaRecurrent B Acute Lymphoblastic LeukemiaRecurrent B-Cell Prolymphocytic Leukemia+15 more
Sumithira Vasu 54
Testing effectiveness (Phase 2)Study completedNCT00085696
What this trial is testing

VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma

Who this might be right for
B-Cell LymphomaFollicular LymphomaMarginal Lymphoma
Millennium Pharmaceuticals, Inc. 66
Next Page